Evaluation of a safe neutrophil count for cessation of intravenous antibiotics and early hospital discharge in stable, afebrile patients recovering after acute myeloid leukemia therapy or an autograft

References

• Gea-Banacloche J. Evidence-based approach to treatment of febrile neutropenia in hematologic malignancies. Hematology Am Soc Hematol Educ Program. 2013;2013:414–422.
   PubMedGoogle Scholar
• Averbuch D, Cordonnier C, Livermore DM, et al. Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European conference on infections in leukemia (ECIL-4, 2011). Haematologica. 2013;98(12):1836–1847.
   PubMed Web of Science ®Google Scholar
• Klastersky J, de Naurois J, Rolston K, et al. Management of febrile neutropaenia: ESMO clinical practice guidelines. Ann Oncol. 2016;27(suppl 5):v111–v118.
   PubMed Web of Science ®Google Scholar
• Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. Clin Infect Dis. 2011;52(4):e56-93–e93.
   PubMed Web of Science ®Google Scholar
• Averbuch D, Orasch C, Cordonnier C, et al. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Cconference on infections in leukemia. Haematologica. 2013;98(12):1826–1835.
   PubMed Web of Science ®Google Scholar
• Righi E, Peri AM, Harris PNA, et al. Global prevalence of carbapenem resistance in neutropenic patients and association with mortality and carbapenem use: systematic review and meta-analysis. J Antimicrob Chemother. 2017;72(3):668–677.
   PubMed Web of Science ®Google Scholar
• Gudiol C, Tubau F, Calatayud L, et al. Bacteraemia due to multidrug-resistant gram-negative bacilli in cancer patients: risk factors, antibiotic therapy and outcomes. J Antimicrob Chemother. 2011;66(3):657–663.
   PubMed Web of Science ®Google Scholar
• Schalk E, Bohr URM, König B, et al. Clostridium difficile-associated diarrhoea, a frequent complication in patients with acute myeloid leukaemia. Ann Hematol. 2010;89(1):9–14.
   PubMed Web of Science ®Google Scholar
• Lingaratnam S, Slavin MA, Mileshkin L, et al. An Australian survey of clinical practices in management of neutropenic fever in adult cancer patients 2009. Intern Med J. 2011;41(1b):110–120.
   PubMed Web of Science ®Google Scholar
• Slavin MA, Lingaratnam S, Mileshkin L, et al. Use of antibacterial prophylaxis for patients with neutropenia. Australian consensus guidelines 2011 steering committee. Intern Med J. 2011;41(1b):102–109.
   PubMed Web of Science ®Google Scholar
• Mikulska M, Averbuch D, Tissot F, et al. Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines. J Infect. 2018;76(1):20–37.
   PubMed Web of Science ®Google Scholar
• Godwin JE, Kopecky KJ, Head DR, et al. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest oncology group study (9031). Blood. 1998;91(10):3607–3615.
   PubMed Web of Science ®Google Scholar
• Stern A, Carrara E, Bitterman R, et al. Early discontinuation of antibiotics for febrile neutropenia versus continuation until neutropenia resolution in people with cancer. Cochrane Database Syst Rev. 2019;1(1):CD012184.
   PubMedGoogle Scholar
• Mank A, van der Lelie J, de Vos R, et al. Safe early discharge for patients undergoing high dose chemotherapy with or without stem cell transplantation: a prospective analysis of clinical variables predictive for complications after treatment. J Clin Nurs. 2011;20(3-4):388–395.
   PubMed Web of Science ®Google Scholar
• Gil L, Styczynski J, Komarnicki M. Infectious complication in 314 patients after high-dose therapy and autologous hematopoietic stem cell transplantation: risk factors analysis and outcome. Infection. 2007;35(6):421–427.
   PubMed Web of Science ®Google Scholar
• Galloway-Peña JR, Shi Y, Peterson CB, et al. Gut microbiome signatures are predictive of infectious risk following induction therapy for acute myeloid leukemia. Clin Infect Dis. 2020;71(1):63–71.
   PubMed Web of Science ®Google Scholar
• Balsat M, Pillet S, Tavernier E, et al. Human herpesvirus 6 infection after autologous stem cell transplantation: a multicenter prospective study in adult patients. J Infect. 2019;79(1):36–42.
   PubMed Web of Science ®Google Scholar
• Chow V, Dorcy KS, Sandhu R, et al. Evaluation of early discharge after hospital treatment of neutropenic fever in acute myeloid leukemia (AML). Leuk Res Rep. 2013;2(1):26–28.
   PubMedGoogle Scholar
• Halpern AB, Walter RB, Estey EH. Outpatient induction and consolidation care strategies in acute myeloid leukemia. Curr Opin Hematol. 2019;26(2):65–70.
   PubMed Web of Science ®Google Scholar
• Martino M, Console G, Russo L, et al. Autologous stem cell transplantation in patients with multiple myeloma: an activity-based costing analysis, comparing a total inpatient model versus an early discharge model. Clin Lymphoma Myeloma Leuk. 2017;17(8):506–512.
   PubMed Web of Science ®Google Scholar
• Barban A, Coracin FL, Musqueira PT, et al. Analysis of the feasibility of early hospital discharge after autologous hematopoietic stem cell transplantation and the implications to nursing care. Rev Bras Hematol Hemoter. 2014;36(4):264–268.
   PubMedGoogle Scholar
• Martino M, Russo L, Martinello T, et al. A home-care, early discharge model after autografting in multiple myeloma: results of a three-arm prospective, non-randomized study. Leuk Lymphoma. 2015;56(3):801–804.
   PubMed Web of Science ®Google Scholar
• Johnson W, Kerridge I, Milton C, et al. Hospital in the home (HITH) care following autologous stem cell transplantation for lymphoma and multiple myeloma. Aust J Adv Nurs. 2006;23(4):34–39.
   PubMed Web of Science ®Google Scholar